Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

By P. Calverley, Julie A. Anderson, Bartolome Celli, G. Ferguson, C. Jenkins, P. Jones, J. Yates, Jorgen Vestbo. New England Journal of Medicine, 2007

3,269 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/ad851dbad1d6631f1011ab97b54029a53c601281

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. D. Parums
2. J. Wedzicha
3. T. Seemungal
4. P. Barnes
5. P. Calverley

In Pulmonary and Respiratory Medicine

1. D. Parums
2. J. Wedzicha
3. P. Barnes
4. T. Seemungal
5. A. Anzueto
6. Jorgen Vestbo
7. P. Calverley
8. R. Rodríguez-Roisín

Citations in the corpus

• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. (2017, background): “However, survival is not affected by combination therapy.(132,133)”
• Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, positive): “Плановая терапия ингаляционными ГКС не оказывает влияния на постепенное снижение ОФВ1 и не снижает общую смертность пациентов с ХОБЛ [126, 175, 176, 195, 246, 247, 520] (уровень доказательности А).”